Shanghai Zhabei District Central Hospital, Shanghai, China.
Leuk Res. 2012 Jun;36(6):715-9. doi: 10.1016/j.leukres.2011.12.023. Epub 2012 Jan 24.
Twenty-two patients with myelodysplastic syndromes (MDS) were treated with thalidomide plus arsenic trioxide (ATO). Twenty-two MDS patients receiving supportive care were used as controls. The remission was achieved in 4 patients (18.2%) receiving thalidomide/ATO, and none in the control group (p<0.05). Fifteen of 22 patients in the treatment group achieved hematologic improvement (68.2% vs. 27.3% in the control, p<0.05). The progression-free survival was longer in the treatment group than that in the control (26 vs. 10 months, p<0.05). The overall survival was also longer in the treatment group than that in the control (36 vs. 16 months, p<0.05). No severe adverse reactions were observed. These preliminary findings suggest that thalidomide/ATO combination treatment is effective and safe for MDS.
22 例骨髓增生异常综合征（MDS）患者接受沙利度胺联合三氧化二砷（ATO）治疗。22 例接受支持治疗的 MDS 患者作为对照组。接受沙利度胺/ATO 治疗的 4 例患者（18.2%）达到缓解，对照组无一例缓解（p<0.05）。治疗组 22 例患者中有 15 例获得血液学改善（68.2%比对照组的 27.3%，p<0.05）。治疗组无进展生存期长于对照组（26 个月比 10 个月，p<0.05）。治疗组总生存期长于对照组（36 个月比 16 个月，p<0.05）。未观察到严重不良反应。这些初步研究结果表明，沙利度胺/ATO 联合治疗对 MDS 是有效且安全的。
